tiprankstipranks
Trending News
More News >
Immunome (IMNM)
NASDAQ:IMNM
US Market

Immunome (IMNM) Income Statement

Compare
434 Followers

Immunome Income Statement

Last quarter (Q4 2025), Immunome's total revenue was $0.00, a decrease of -100.00% from the same quarter last year. In Q4, Immunome's net income was $-69.90M. See Immunome’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 6.94M$ 9.04M$ 14.02M$ 0.00$ 0.00
Gross Profit
$ 3.99M$ 9.04M$ 14.02M$ 0.00$ 0.00
Operating Expenses
$ 218.10M$ 314.84M$ 123.55M$ 36.90M$ 25.20M
Depreciation and Amortization
$ 2.96M$ 2.10M$ 728.00K$ 631.00K$ 755.00K
EBITDA
$ -211.16M$ -151.35M$ -28.00M$ -36.27M$ -24.45M
Operating Income
$ -214.11M$ -305.80M$ -109.53M$ -36.90M$ -25.20M
Other Income/Expenses
$ 1.72M$ 12.84M$ 2.72M$ 5.00K$ 493.00K
Pretax Income
$ -212.39M$ -292.96M$ -106.81M$ -36.90M$ -24.71M
Net Income
$ -212.39M$ -292.96M$ -106.81M$ -36.90M$ -24.71M
Per Share Metrics
Basic EPS
$ -2.43$ -5.00$ -5.38$ -3.09$ -2.14
Diluted EPS
$ -2.43$ -5.00$ -5.38$ -3.09$ -2.14
Weighted Average Shares Outstanding
87.35M 58.64M 19.84M 12.13M 11.54M
Weighted Average Shares Outstanding (Diluted)
87.35M 58.64M 19.84M 12.13M 11.54M
Currency in USD

Immunome Earnings and Revenue History